Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 8/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | GALK1 | P51570 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044800 | 0.94 | HCAR3 (0.60) | HCAR3GAARXFP1TTRGALK1 | |
| SCHEMBL6044172 | 0.83 | HCAR3 (0.58) | HCAR3GAARXFP1GALK1ALDH1A1 | |
| SCHEMBL6044613 | 0.78 | HCAR3 (0.60) | HCAR3GAARXFP1GALK1ALDH1A1 | |
| SCHEMBL6043957 | 0.74 | HCAR3 (1.00) | HCAR3GAARXFP1GALK1TP53 | |
| SCHEMBL6043674 | 0.71 | HCAR3 (0.58) | HCAR3GAARXFP1GALK1MGAM | |
| SCHEMBL6044966 | 0.71 | HCAR3 (0.48) | HCAR3GAAALDH1A1TSHR | |
| SCHEMBL29490305 | 0.71 | HCAR3 (0.78) | HCAR3GAARXFP1GALK1ALDH1A1 | |
| SCHEMBL22862503 | 0.71 | HCAR3 (0.78) | HCAR3GAARXFP1GALK1ALDH1A1 | |
| SCHEMBL6044765 | 0.69 | HCAR3 (0.41) | HCAR3GAATTRMGAMAMY1A | |
| SCHEMBL6044413 | 0.69 | HCAR3 (0.44) | HCAR3TTRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885GAA 70/4885RXFP1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.